Evidence map›Paper›PMID 39084187›Full record

ArticleCellular immunology

R406 reduces lipopolysaccharide-induced neutrophil activation.

Seth Warner, Heather L Teague, Marcos J Ramos-Benitez, Sumith Panicker, Kiana Allen, Salina Gairhe, Tom Moyer, Bindu Parachalil Gopalan, Iyadh Douagi, Arun Shet and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular immunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. SARS-CoV-2 Immune Complex-Mediated Neutrophil Activation.Open forum infectious diseases · 2025
    Trial
  2. Article
  3. Review
  4. Article
  5. Breaking the Stalemate: Advancing Sepsis Therapeutics Beyond Supportive Care.Public health reports (Washington, D.C. : 1974) · 2026
    Article
  6. Association of CD16Journal of inflammation research · 2026
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Seth WarnerCritical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Heather L TeagueCritical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Marcos J Ramos-BenitezBasic Science Department, Microbiology Division, School of Medicine, Ponce Health Sciences University, Ponce, PR, USA.
Sumith PanickerLaboratory of Vascular Thrombosis and Inflammation, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Kiana AllenCritical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Salina GairheCritical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Tom MoyerFlow Cytometry Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Bindu Parachalil GopalanLaboratory of Sickle Thrombosis and Vascular Biology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Iyadh DouagiFlow Cytometry Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA; NIH Center for Human Immunology, Inflammation, and Autoimmunity, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Arun ShetLaboratory of Sickle Thrombosis and Vascular Biology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Yogendra KanthiLaboratory of Vascular Thrombosis and Inflammation, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Anthony F SuffrediniCritical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Daniel S ChertowCritical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jeffrey R StrichCritical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA. Electronic address: jeffrey.strich@nih.gov.

Funding

Infectious Diseases Research Technologies Core - BethesdaZICAI001051 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2009 to 2025
$226.1M
Tracking and Evaluation CoreU54GM133807 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI LUCIANO, CARLOS A., MOROU-BERMUDEZ, EVANGELIA · 2020 to 2024
$17.7M
Human Translational Studies of Vascular Thrombosis and InflammationZIAHL006262 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI KANTHI, YOGENDRA · 2021 to 2025
$4.7M
Vascular Immunobiology Mechanistic and Translational StudiesZIAHL006267 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI KANTHI, YOGENDRA · 2021 to 2025
$4.6M
Unraveling Cytotoxic and Thrombotic Signals in Host-defense ResponsesZIAHL006263 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI KANTHI, YOGENDRA · 2021 to 2025
$3.5M
Obtaining Samples from Human Subjects to Facilitate Basic, Translational and Clinical ResearchZIACL009029 · CLC · CLINICAL CENTER · PI SOLOMON, MICHAEL · 2018 to 2025
$0k
Intramural NIH HHS Z99 CL999999Intramural NIH HHS ZIA HL006262Intramural NIH HHS ZIA HL006263Intramural NIH HHS ZIA HL006267
6 · The paper itself

Abstract

Modulating SYK has been demonstrated to have impacts on pathogenic neutrophil responses in COVID-19. During sepsis, neutrophils are vital in early bacterial clearance but also contribute to the dysregulated immune response and organ injury when hyperactivated. Here, we evaluated the impact of R406, the active metabolite of fostamatinib, on neutrophils stimulated by LPS. We demonstrate that R406 was able to effectively inhibit NETosis, degranulation, ROS generation, neutrophil adhesion, and the formation of CD16

Indexed as

AminopyridinesLipopolysaccharidesNeutrophil ActivationNeutrophilsCell AdhesionCell DegranulationCOVID-19Extracellular TrapsHumansImidazolesInterleukin-8MorpholinesPhagocytosisPyridinesPyrimidinesReactive Oxygen SpeciesAminopyridinesfostamatinibImidazolesInterleukin-8LipopolysaccharidesMorpholinesPyridinesPyrimidinesReactive Oxygen SpeciesReceptors, IgGSyk KinaseSYK protein, humanNeutrophilsSepsisSpleen tyrosine kinase

Identifiers

PMID39084187
PMCPMC11387147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.